Free Trial
NASDAQ:MRSN

Mersana Therapeutics Q2 2023 Earnings Report

Mersana Therapeutics logo
$0.34 +0.01 (+3.65%)
As of 02:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mersana Therapeutics EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Mersana Therapeutics Revenue Results

Actual Revenue
$10.70 million
Expected Revenue
$12.93 million
Beat/Miss
Missed by -$2.23 million
YoY Revenue Growth
+148.80%

Mersana Therapeutics Announcement Details

Quarter
Q2 2023
Time
Before Market Opens
Conference Call Date
Tuesday, August 8, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Mersana Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Mersana Therapeutics Earnings Headlines

Mersana Therapeutics Inc (MRSN) - Investing.com
Drilling With a $3.5B Discovery Partner in Its Corner
A small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveries and billion-dollar takeouts. Its $3.5B discovery partner has already spent over $2.5M prepping the targets, which include historical grades up to 83.2 g/t gold and 30% zinc. And with just a $10M market cap and a float tightly held by institutions and insiders, this junior is positioned for outsized upside on a discovery.
Q1 2025 Mersana Therapeutics Inc Earnings Call
See More Mersana Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mersana Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mersana Therapeutics and other key companies, straight to your email.

About Mersana Therapeutics

Mersana Therapeutics (NASDAQ:MRSN) is a clinical-stage biopharmaceutical company focused on the discovery and development of antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2003 and headquartered in Cambridge, Massachusetts, Mersana leverages its proprietary Dolaflexin® and Aquaflexin® ADC platforms to create targeted therapeutics designed to deliver potent cytotoxic agents selectively to tumor cells. The company’s research emphasizes optimizing linker chemistry and payload potency to maximize tumor cell killing while minimizing off-target toxicity.

Mersana’s lead clinical candidate, upifitamab rilsodotin (formerly XMT-1536), is designed to target NaPi2b-expressing cancers, including ovarian and non-small cell lung cancer. Additional preclinical and clinical programs include XMT-1592, which targets the folate receptor alpha, and XMT-1660, which focuses on HER2-expressing tumors with a novel exatecan payload. The company’s Aquaflexin platform further enables the development of highly hydrophilic ADCs that may improve tolerability and expand the scope of potential cancer targets.

In addition to its internal research efforts, Mersana has established strategic collaborations with global biopharmaceutical organizations, including Takeda, Merck, Pfizer and AstraZeneca. These partnerships aim to accelerate the development and commercialization of ADCs across multiple therapeutic areas and geographic markets. Through collaborative agreements, Mersana gains access to complementary expertise and resources while retaining global development and commercialization rights for several of its proprietary candidates.

Under the leadership of President and Chief Executive Officer Geoffrey C. Chase, Mersana continues to advance its product pipeline through clinical trials and regulatory interactions. The company’s board and management team comprise seasoned professionals with extensive experience in oncology drug development, regulatory affairs and commercial strategy. As Mersana progresses toward potential regulatory submissions and commercialization milestones, it remains committed to delivering next-generation ADC therapies to improve outcomes for patients with hard-to-treat cancers.

View Mersana Therapeutics Profile

More Earnings Resources from MarketBeat